These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 27402915)

  • 21. Efficacy of tumour necrosis factor antagonists on remission, colectomy and hospitalisations in ulcerative colitis: Meta-analysis of placebo-controlled trials.
    Lopez A; Ford AC; Colombel JF; Reinisch W; Sandborn WJ; Peyrin-Biroulet L
    Dig Liver Dis; 2015 May; 47(5):356-64. PubMed ID: 25661014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of the Risk of Relapse in Ulcerative Colitis According to the Degree of Mucosal Healing (Mayo 0 vs 1): A Longitudinal Cohort Study.
    Barreiro-de Acosta M; Vallejo N; de la Iglesia D; Uribarri L; Bastón I; Ferreiro-Iglesias R; Lorenzo A; Domínguez-Muñoz JE
    J Crohns Colitis; 2016 Jan; 10(1):13-9. PubMed ID: 26351390
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy and Safety of Adalimumab in Moderately to Severely Active Cases of Ulcerative Colitis: A Meta-Analysis of Published Placebo-Controlled Trials.
    Zhang ZM; Li W; Jiang XL
    Gut Liver; 2016 Mar; 10(2):262-74. PubMed ID: 26780088
    [TBL] [Abstract][Full Text] [Related]  

  • 24. One-year maintenance outcomes among patients with moderately-to-severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2.
    Sandborn WJ; Colombel JF; D'Haens G; Van Assche G; Wolf D; Kron M; Lazar A; Robinson AM; Yang M; Chao JD; Thakkar R
    Aliment Pharmacol Ther; 2013 Jan; 37(2):204-13. PubMed ID: 23173821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effectiveness of adalimumab for the treatment of ulcerative colitis in clinical practice: comparison between anti-tumour necrosis factor-naïve and non-naïve patients.
    Iborra M; Pérez-Gisbert J; Bosca-Watts MM; López-García A; García-Sánchez V; López-Sanromán A; Hinojosa E; Márquez L; García-López S; Chaparro M; Aceituno M; Calafat M; Guardiola J; Belloc B; Ber Y; Bujanda L; Beltrán B; Rodríguez-Gutiérrez C; Barrio J; Cabriada JL; Rivero M; Camargo R; van Domselaar M; Villoria A; Schuterman HS; Hervás D; Nos P;
    J Gastroenterol; 2017 Jul; 52(7):788-799. PubMed ID: 27722996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid Changes in Laboratory Parameters and Early Response to Adalimumab: A Pooled Analysis From Patients With Ulcerative Colitis in Two Clinical Trials.
    Hanauer S; Sandborn WJ; Colombel JF; Vermeire S; Petersson J; Kligys K; Zhou Q; Lazar A; Reinisch W
    J Crohns Colitis; 2019 Sep; 13(9):1227-1233. PubMed ID: 30726897
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.
    Nakarai A; Kato J; Hiraoka S; Takashima S; Takei D; Inokuchi T; Sugihara Y; Takahara M; Harada K; Okada H
    World J Gastroenterol; 2016 Jun; 22(21):5079-87. PubMed ID: 27275100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Infliximab trough concentrations during maintenance therapy are associated with endoscopic and histologic healing in ulcerative colitis.
    Papamichael K; Rakowsky S; Rivera C; Cheifetz AS; Osterman MT
    Aliment Pharmacol Ther; 2018 Feb; 47(4):478-484. PubMed ID: 29210094
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Infliximab Exposure-Response Relationship and Thresholds Associated With Endoscopic Healing in Patients With Ulcerative Colitis.
    Vande Casteele N; Jeyarajah J; Jairath V; Feagan BG; Sandborn WJ
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1814-1821.e1. PubMed ID: 30613004
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outpatient Ulcerative Colitis Primary Anti-TNF Responders Receiving Adalimumab or Infliximab Maintenance Therapy Have Similar Rates of Secondary Loss of Response.
    Ma C; Huang V; Fedorak DK; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    J Clin Gastroenterol; 2015 Sep; 49(8):675-82. PubMed ID: 25389599
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and prognostic role of mucosal healing in patients with Crohn's disease and ulcerative colitis after one-year of biological therapy.
    Farkas K; Lakatos PL; Szűcs M; Pallagi-Kunstár É; Bálint A; Nagy F; Szepes Z; Vass N; Kiss LS; Wittmann T; Molnár T
    World J Gastroenterol; 2014 Mar; 20(11):2995-3001. PubMed ID: 24659890
    [TBL] [Abstract][Full Text] [Related]  

  • 32. INFLIXIMAB AND ADALIMUMAB SERUM TROUGH CONCENTRATIONS THRESHOLD ASSOCIATED WITH DEEP REMISSION IN INFLAMMATORY BOWEL DISEASE.
    Pascual-Marmaneu Ó; Belles-Medall MD; Ferrando-Piqueres R; Almela-Notari P; Mendoza-Aguilera M; Álvarez-Martín T
    Farm Hosp; 2021 Aug; 45(5):225-233. PubMed ID: 34806581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TNF Therapy Response in Patients with Ulcerative Colitis Is Associated with Colonic Antimicrobial Peptide Expression and Microbiota Composition.
    Magnusson MK; Strid H; Sapnara M; Lasson A; Bajor A; Ung KA; Öhman L
    J Crohns Colitis; 2016 Aug; 10(8):943-52. PubMed ID: 26896085
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis.
    Arias MT; Vande Casteele N; Vermeire S; de Buck van Overstraeten A; Billiet T; Baert F; Wolthuis A; Van Assche G; Noman M; Hoffman I; D'Hoore A; Gils A; Rutgeerts P; Ferrante M
    Clin Gastroenterol Hepatol; 2015 Mar; 13(3):531-8. PubMed ID: 25117777
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Four-year maintenance treatment with adalimumab in patients with moderately to severely active ulcerative colitis: Data from ULTRA 1, 2, and 3.
    Colombel JF; Sandborn WJ; Ghosh S; Wolf DC; Panaccione R; Feagan B; Reinisch W; Robinson AM; Lazar A; Kron M; Huang B; Skup M; Thakkar RB
    Am J Gastroenterol; 2014 Nov; 109(11):1771-80. PubMed ID: 25155227
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative efficacy of golimumab, infliximab, and adalimumab for moderately to severely active ulcerative colitis: a network meta-analysis accounting for differences in trial designs.
    Thorlund K; Druyts E; Toor K; Mills EJ
    Expert Rev Gastroenterol Hepatol; 2015 May; 9(5):693-700. PubMed ID: 25763862
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Infliximab and adalimumab concentrations and anti-drug antibodies in inflammatory bowel disease control using New Zealand assays.
    Barclay ML; Karim S; Helms ETJ; Keating PE; Hock B; Stamp LK; Schultz M
    Intern Med J; 2019 Apr; 49(4):513-518. PubMed ID: 30091273
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Open-label study of adalimumab in patients with ulcerative colitis including those with prior loss of response or intolerance to infliximab.
    Afif W; Leighton JA; Hanauer SB; Loftus EV; Faubion WA; Pardi DS; Tremaine WJ; Kane SV; Bruining DH; Cohen RD; Rubin DT; Hanson KA; Sandborn WJ
    Inflamm Bowel Dis; 2009 Sep; 15(9):1302-7. PubMed ID: 19408340
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Infliximab biosimilar CT-P13 therapy is effective in maintaining endoscopic remission in ulcerative colitis - results from multicenter observational cohort.
    Bálint A; Rutka M; Kolar M; Bortlik M; Duricova D; Hruba V; Lukas M; Mitrova K; Malickova K; Lukas M; Szepes Z; Nagy F; Palatka K; Lovas S; Végh Z; Kürti Z; Csontos Á; Miheller P; Nyári T; Bor R; Milassin Á; Fábián A; Szántó K; Lakatos PL; Molnár T; Farkas K
    Expert Opin Biol Ther; 2018 Nov; 18(11):1181-1187. PubMed ID: 30277084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Adalimumab treatment of anti-TNF-naïve patients with ulcerative colitis: Deep remission and response factors.
    Muñoz-Villafranca C; Ortiz de Zarate J; Arreba P; Higuera R; Gómez L; Ibáñez S; Merino O; Muñagorri A; Ogueta M; Rodriguez C; Nantes O; Ramirez de la Piscina P; Rodríguez I; Bernal A; Arévalo J; Cabriada J
    Dig Liver Dis; 2018 Aug; 50(8):812-819. PubMed ID: 29625907
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.